The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

The Oncodetect test is a highly sensitive, tumor-informed assay that empowers oncologists and patients with critical insights ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

In fact, eight times out of ten, EXAS stock has popped higher in the week following the flashing of the 2-8-D sequence, with a median return of 4.91%. It’s possible, then, that within a week or two, ...

University research in Wisconsin led to $500 million Third Wave business, screening tests for cancer, including Cologuard ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after ...

Amid the rising prevalence of cancer worldwide, significant strides have been made in the cancer diagnostics market to improve treatment outcomes and survival rates. According to Roots Analysis, the ...

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

Review quarterly and annual revenue, net income, and cash flow for Exact Sciences Corp (EXAS:XNAS) stock through the last fiscal year.

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...